|
|
Crucell is a fully-integrated biopharmaceutical company. We focus on developing, producing and marketing products that combat infectious diseases. We are the largest independent vaccine company in the world.
Headquartered in Leiden, The Netherlands, Crucell currently employs about 1100 people and has subsidiaries in Switzerland, Spain, Sweden, Italy, Korea and the United States. Crucell N.V. is listed on Euronext and NASDAQ (CRXL) and the SWX Swiss Exchange (CRX). At Crucell, we’re bringing innovation to global health.
For more information, please visit the About Us section.
As the sixth largest vaccine company worldwide, Crucell presents a strong portfolio of products:
Quinvaxem® - the fully-liquid vaccine for protection against five important childhood diseases
Hepavax-Gene® - a recombinant hepatitis B vaccine
MoRu-Viraten® - a safe, well-tolerated and effective vaccine for protection against measles and rubella in children, adolescents and adults
Inflexal® V - the virosomal vaccine against influenza
Epaxal® - the only aluminium-free hepatitis A vaccine, without preservatives or antibiotics
Vivotif® - the only oral anti-typhoid vaccine
Dukoral® - the only internationally licensed oral vaccine with documented efficacy against diarrhea caused by cholera
Crucell has a broad development pipeline, including vaccines and proteins. Several Crucell products are based on our unique PER.C6®production technology. Crucell licenses this and other cutting edge technologies to the biopharmaceutical industry. Important partners and licensees are DSM Biologics, sanofi aventis, GSK, Merck & Co. and the US National Institutes of Health (NIH)..
|
About Us
